Combo Tx May Improve Anticoagulant Activity, Reduce Hypertensive Damage

November 15, 2018

Coagulant activity was improved with the use of both anticoagulation and antihypertensive therapies in combination.

Diuretic Regimen vs Telmisartan Combo in Hypertension With Diabetes

November 15, 2018

Previous studies on the suitability of diuretics for patients with hypertension and diabetes reveal inconsistencies.

Hypertension Combo Pill Recalled Due to Presence of Probable Carcinogen

By November 09, 2018

Losartan Potassium and Hydrochlorothiazide Tablets are approved to treat hypertension, alone or in combination with other antihypertensive drugs.

Outcomes of hypertension treatment in low-risk patients

November 05, 2018

The benefit of treating low-risk patients with mild (sustained blood pressure of 140/90-159/99mmHg) hypertension is not clear as these patients are not frequently included in trials given the low incidence rate of major cardiovascular events.

Home BP of 130/80mmHg ID'd as Threshold for Stage 1 Hypertension

November 01, 2018

The researchers found that the regression-derived thresholds for home BP corresponding to clinic BP for stage 1 hypertension were 129/80, 130/80, and 126/78mmHg for blacks, whites, and Hispanics, respectively, among untreated participants.

Severe Acute Respiratory Distress Syndrome Following HCTZ Administration

By October 31, 2018

"One of the most commonly prescribed antihypertensives, HCTZ is associated with rare cases of pulmonary edema, which typically develop within minutes to hours of the initial dose of the medication," the study authors stated.

Another Antihypertensive Recalled Due to Potentially Carcinogenic Impurity

By October 31, 2018

The impurity was identified following laboratory testing conducted by the Food and Drug Administration (FDA); this is the first non-valsartan product that the Agency has found to contain NDEA.

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

By October 29, 2018

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.

Intensive blood pressure lowering favored to not induce kidney disease

October 26, 2018

Patients managed with intensive blood pressure reduction were found to have significantly greater decreases in kidney damage biomarkers compared to standard blood pressure management.

Macitentan Tolerated in Portopulmonary Hypertension

October 11, 2018

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Sexual Harassment, Assault Tied to Women's Health Issues

October 05, 2018

Among women not taking antihypertensives, sexual harassment was correlated with significantly increased odds of stage 1 or 2 hypertension (odds ratio, 2.36) as well as clinically poor sleep (odds ratio, 1.89) after adjustment for covariates.

Southern diet may be largest factor in higher hypertension rates in black populations

October 03, 2018

The higher rate of hypertension in black patients than white patients was most strongly influenced by a Southern diet in both men and women.

HTN Tx Intensification Common Upon Discharge in US Vets

September 19, 2018

Fourteen percent of patients were discharged with intensified antihypertensive treatment, more than half of whom had well-controlled blood pressure prior to hospital admission.

Hydralazine Linked to Amenorrhea in Premenopausal Patient

By September 18, 2018

This case highlights a possible relationship between the administration of hydralazine and the development of amenorrhea.

Second Impurity Identified in Recalled Valsartan Products

By September 17, 2018

In July, several valsartan medications were recalled due to the detection of N-nitrosodimethylamine, an impurity classified as a probable human carcinogen.

AHA: Resistant Hypertension Diagnosis, Tx Guidelines Updated

September 14, 2018

Ruling out Rx non-compliance, white coat syndrome, and interfering medications necessary

Cancer Risk Associated With Recalled Valsartan Products Examined

September 14, 2018

For single cancer outcomes, risk for colorectal, uterine cancer increased, but not significantly so

Single, Fixed-Dose Combo Pills Improve Hypertension Outcomes

September 12, 2018

Researchers compared clinical outcomes and medication adherence for patients prescribed 1 angiotensin-converting enzyme inhibitor or angiotensin II-receptor blocker plus 1 thiazide diuretic, either as a single-pill FDC or as a multi-pill combination.

Asthma Medicine Recalled Due to Tablet Mix-Up That May Pose Safety Risk

By August 31, 2018

The risk of a mixing-up the treatments is especially high for pregnant women, says the Food and Drug Administration (FDA), as losartan is indicated to treat high blood pressure and could harm or kill a fetus.

Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic

By August 29, 2018

To date, there have been no reports of any adverse events related to this recall.

Triple combo antihypertension Tx improves blood pressure control in hypertension

August 16, 2018

In this randomized controlled trial, patients receiving triple combination antihypertension therapy (TCAT) were more likely to achieve their blood pressure target compared to those with usual care at 6 months.

Case: Hypertensive Crisis Following Use of Armodafinil + MAOI

By August 15, 2018

This case involved a 36-year-old female with bipolar disorder who presented to the emergency department (ED) with blurry vision, neck stiffness and the "worst headache of (her) life" after taking armodafinil with tranylcypromine.

Labetalol Use Up for Patients With Preeclampsia and Asthma

August 15, 2018

The researchers found that patients with asthma used carboprost less frequently than patients with no asthma (11.4 vs 18.0%) compared with intravenous labetalol, which was used more often among patients with a diagnosis of asthma than those without (18.5 vs 16.7%).

Triple Combo Blood Pressure Pill Can Improve BP Control

August 15, 2018

The researchers found that the proportion of patients achieving target BP was increased with the triple combination pill versus usual care at 6 months (70 vs 55%; risk difference, 12.7%).

Kapspargo Sprinkle Available to Treat Hypertension, Angina, Heart Failure

By August 07, 2018

For patients unable to swallow an intact capsule, the pellets can be sprinkled over soft food (eg, applesauce, yogurt, pudding) or given via a nasogastric (NG) tube.

Use of BP-Interfering Medications Examined Among Patients With Hypertension

By August 02, 2018

To better understand the real-world use of these agents among patients with hypertension, researchers conducted a retrospective drug utilization study using medical and prescription claims from the Marketscan database (January 2008 to December 2014).

Tool Improves Identification of Undiagnosed Hypertension

July 30, 2018

The tool was applied using medical billing data alone and in combination with clinical data from 8.92 million patients from 25 organizations participating in the American Medical Group Association national learning collaborative to calculate and compare predicted and observed adult hypertension prevalence.

Use of 2017 ACC/AHA Guidelines Would Increase HTN Prevalence

July 27, 2018

The researchers found that adoption of the 2017 ACC/AHA hypertension guidelines in the United States would label 70.1 million people (63%) aged 45 to 75 years with hypertension.

Modifiable Midlife Risk Factors Linked to Late-Onset Epilepsy

July 25, 2018

"Although stroke and dementia were both associated with late-onset epilepsy, vascular and lifestyle risk factors were significant even in the absence of stroke or dementia," the authors write.

Heart Meds Recalled After Discovery of Possible Carcinogenic Impurity

By July 16, 2018

As valsartan is used to treat various cardiovascular conditions including heart failure and hypertension, patients should continue to take their medications until they have a replacement product,